Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COLL Collegium Pharmaceutical	$30.90 +1.8%	$29.30	$23.23 ▼ $42.29	$975.20M	0.64	399,434 shs	431,680 shs
PAHC Phibro Animal Health	$29.90 +6.8%	$23.60	$16.16 ▼ $30.59	$1.13B	0.75	215,504 shs	557,250 shs
PVLA Palvella Therapeutics	$24.90 +3.2%	$23.30	$6.20 ▼ $29.27	$266.66M	-0.11	130,255 shs	64,899 shs
RCUS Arcus Biosciences	$8.23 -2.8%	$8.83	$6.50 ▼ $18.98	$896.85M	0.8	879,789 shs	858,707 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COLL Collegium Pharmaceutical	0.00%	+1.47%	+0.56%	+10.92%	-5.62%
PAHC Phibro Animal Health	0.00%	+9.08%	+16.24%	+50.00%	+66.11%
PVLA Palvella Therapeutics	0.00%	+9.24%	-5.04%	+20.18%	+2,411,999,900.00%
RCUS Arcus Biosciences	0.00%	+6.56%	-15.31%	+16.36%	-40.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COLL Collegium Pharmaceutical	4.2522 of 5 stars	3.4	1.0	0.0	3.0	3.1	0.8	2.5
PAHC Phibro Animal Health	3.6567 of 5 stars	0.9	2.0	2.5	1.1	3.0	3.3	2.5
PVLA Palvella Therapeutics	3.3434 of 5 stars	3.6	0.0	0.0	0.0	2.7	4.2	0.6
RCUS Arcus Biosciences	2.7531 of 5 stars	4.4	3.0	0.0	0.0	0.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COLL Collegium Pharmaceutical	2.75	Moderate Buy	$43.75	41.59% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-18.39% Downside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	85.89% Upside
RCUS Arcus Biosciences	2.89	Moderate Buy	$21.29	158.64% Upside

Current Analyst Ratings Breakdown

Latest PVLA, PAHC, COLL, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/9/2025	COLL Collegium Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$36.00 ➝ $37.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COLL Collegium Pharmaceutical	$631.45M	1.57	$12.56 per share	2.46	$7.10 per share	4.35
PAHC Phibro Animal Health	$1.02B	1.19	$2.26 per share	13.25	$6.34 per share	4.72
PVLA Palvella Therapeutics	$42.81M	6.43	N/A	N/A	$5.58 per share	4.46
RCUS Arcus Biosciences	$258M	3.38	N/A	N/A	$5.30 per share	1.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COLL Collegium Pharmaceutical	$69.19M	$1.22	25.33	5.13	N/A	6.61%	99.08%	15.14%	8/6/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	38.33	14.24	0.47	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)

Latest PVLA, PAHC, COLL, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/8/2025	Q1 2025	COLL Collegium Pharmaceutical	$1.50	$1.49	-$0.01	$0.07	$174.96 million	$177.76 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.61%	N/A	61.54%	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Latest PVLA, PAHC, COLL, and RCUS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COLL Collegium Pharmaceutical	3.30	1.08	1.01
PAHC Phibro Animal Health	2.67	2.91	1.23
PVLA Palvella Therapeutics	N/A	8.84	8.84
RCUS Arcus Biosciences	0.09	5.37	5.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COLL Collegium Pharmaceutical	N/A
PAHC Phibro Animal Health	99.34%
PVLA Palvella Therapeutics	40.11%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
COLL Collegium Pharmaceutical	2.51%
PAHC Phibro Animal Health	50.07%
PVLA Palvella Therapeutics	20.50%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COLL Collegium Pharmaceutical	210	32.13 million	31.33 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable

PVLA, PAHC, COLL, and RCUS Headlines

Recent News About These Companies

Arcus Biosciences (NYSE:RCUS) Trading Down 2.9% - Here's What Happened

July 3, 2025 | marketbeat.com

Arcus Biosciences Presents First Postive Data for Oral Metastatic Kidney Cancer Treatment

July 1, 2025 | msn.com

Arcus Biosciences (NYSE:RCUS) Trading Down 6.3% - Here's What Happened

June 27, 2025 | marketbeat.com

Incyte, FDA, Sun Pharma and more—Chutes & Ladders

June 27, 2025 | fiercebiotech.comF

Arcus Biosciences Announces New Employment Inducement Grants - Business Wire

June 26, 2025 | businesswire.com

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

June 26, 2025 | msn.com

Precision BioSciences Shares Surge Following FDA Rare Pediatric Disease Designation

June 25, 2025 | msn.com

Precision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%

June 25, 2025 | msn.com

Arcus Biosciences, Inc. (RCUS) Cash Flow - Yahoo Finance

June 24, 2025 | finance.yahoo.com

RCUS Arcus Biosciences, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Arcus Biosciences Announces New Employment Inducement Grants

June 24, 2025 | businesswire.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Moderate Buy" by Analysts

June 23, 2025 | marketbeat.com

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

June 13, 2025 | fiercebiotech.comF

Arcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?

June 11, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)

June 11, 2025 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

June 10, 2025 | businesswire.com

Research Analysts Offer Predictions for RCUS FY2026 Earnings

June 10, 2025 | marketbeat.com

H.C. Wainwright maintains Buy rating for Arcus Biosciences stock

June 4, 2025 | investing.com

Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg

June 2, 2025 | biospace.comB

Arcus unveils kidney cancer data as it eyes Phase III challenge to Merck’s Welireg

June 2, 2025 | thepharmaletter.comT

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of ...

June 1, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Tesla Bulls and Bears Collide: What Investors Should Know
By Sam Quirke | June 18, 2025
View Tesla Bulls and Bears Collide: What Investors Should Know

PVLA, PAHC, COLL, and RCUS Company Descriptions

Collegium Pharmaceutical NASDAQ:COLL

$30.90 +0.55 (+1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$31.06 +0.17 (+0.53%)

As of 05:36 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Phibro Animal Health NASDAQ:PAHC

$29.90 +1.90 (+6.79%)

Closing price 04:00 PM Eastern

Extended Trading

$29.68 -0.22 (-0.74%)

As of 07:35 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Palvella Therapeutics NASDAQ:PVLA

$24.90 +0.78 (+3.23%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Arcus Biosciences NYSE:RCUS

$8.23 -0.24 (-2.83%)

As of 03:59 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time